Log in to your Inderes Free account to see all free content on this page.
Gubra
282 DKK +1.81%HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. See disclaimer.
12 investors are following this company
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Revenue
205.01M
EBIT %
-23.25 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GUBRA
Daily low / high price
278 / 285
DKK
Market cap
4.61B DKK
Turnover
2.7M DKK
Volume
9.6K
Latest research
Latest videos
Financial calendar
Interim report
23.08.2024
ShowingAll content types
RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio